These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 29955492)

  • 21. Clinical implications of serum protein binding in epileptic children during sodium valproate maintenance therapy.
    Yu HY
    Ther Drug Monit; 1984; 6(4):414-23. PubMed ID: 6440321
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pharmacokinetic variability of valproate in women of childbearing age.
    Johannessen Landmark C; Burns ML; Baftiu A; Farmen AH; Lossius MI; Johannessen SI; Tomson T
    Epilepsia; 2017 Oct; 58(10):e142-e146. PubMed ID: 28833045
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of serum albumin on free fractions of phenobarbital and valproic acid in patients with convulsive seizures.
    Sadahiro N; Kodama S; Matsui T; Komatsu M; Matsuo T
    Brain Dev; 1985; 7(4):377-84. PubMed ID: 3933372
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Predicting Unbound Phenytoin Concentrations: Effects of Albumin Concentration and Kidney Dysfunction.
    Montgomery MC; Chou JW; McPharlin TO; Baird GS; Anderson GD
    Pharmacotherapy; 2019 Jul; 39(7):756-766. PubMed ID: 31067355
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Enteral administration of protein supplement and valproate: A potential pharmacokinetic interaction.
    VandenBerg A; Broadway J
    Ment Health Clin; 2017 Jan; 7(1):10-12. PubMed ID: 29955491
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Valpromide, Valproic acid and removal of small intestine in the treatment of a chronic depression: a case report].
    Benjelloun G; Blandin K; Fossati P
    Encephale; 2004; 30(4):400-3. PubMed ID: 15538315
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Drug interactions of zonisamide with phenytoin and sodium valproate: serum concentrations and protein binding.
    Tasaki K; Minami T; Ieiri I; Ohtsubo K; Hirakawa Y; Ueda K; Higuchi S
    Brain Dev; 1995; 17(3):182-5. PubMed ID: 7573757
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Does lamotrigine influence valproate concentrations?
    Mataringa MI; May TW; Rambeck B
    Ther Drug Monit; 2002 Oct; 24(5):631-6. PubMed ID: 12352935
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Serum protein binding of valproic acid in fetus-mother pairs throughout pregnancy: correlation with oxytocin administration and albumin and free fatty acid concentrations.
    Nau H; Krauer B
    J Clin Pharmacol; 1986 Mar; 26(3):215-21. PubMed ID: 3082943
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Pharmacokinetic aspects of drug effects in vitro: effects of serum protein binding on concentration and teratogenicity of valproic acid and 2-en-valproic acid in whole embryos in culture.
    Lewandowski C; Klug S; Nau H; Neubert D
    Arch Toxicol; 1986 Apr; 58(4):239-42. PubMed ID: 3087328
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [The clinical relevance of serial determinations of plasma concentrations of carbamazepine and sodium valproate].
    Hernández-Fustes OJ; Marcourakis T; de Bittencourt PR
    Rev Neurol; 1999 Jun 1-15; 28(11):1043-7. PubMed ID: 10390769
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Factors Influencing Sodium Valproate Serum Concentrations in Patients with Epilepsy Based on Logistic Regression Analysis.
    Lan X; Mo K; Nong L; He Y; Sun Y
    Med Sci Monit; 2021 Nov; 27():e934275. PubMed ID: 34776507
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Carbamazepine and valproate monotherapy: feasibility, relative safety and efficacy, and therapeutic drug monitoring in manic disorder.
    Vasudev K; Goswami U; Kohli K
    Psychopharmacology (Berl); 2000 May; 150(1):15-23. PubMed ID: 10867972
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Valproic acid in the perinatal period: decreased maternal serum protein binding results in fetal accumulation and neonatal displacement of the drug and some metabolites.
    Nau H; Helge H; Luck W
    J Pediatr; 1984 Apr; 104(4):627-34. PubMed ID: 6423793
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Monitoring Protein-Unbound Valproic Acid Serum Concentrations in Clinical Practice.
    Wallenburg E; Klok B; de Jong K; de Maat M; van Erp N; Stalpers-Konijnenburg S; Essink G; van Luin M
    Ther Drug Monit; 2017 Jun; 39(3):269-272. PubMed ID: 28437285
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Serum protein binding of valproic acid in healthy subjects and in patients with liver disease.
    Urien S; Albengres E; Tillement JP
    Int J Clin Pharmacol Ther Toxicol; 1981 Jul; 19(7):319-25. PubMed ID: 6790449
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Apparent valproic acid neurotoxicity in a hypoalbuminemic patient.
    Gidal BE; Collins DM; Beinlich BR
    Ann Pharmacother; 1993 Jan; 27(1):32-5. PubMed ID: 8381686
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Displacement effect of valproate on bilirubin-albumin binding in human plasma.
    Yu HY; Shen YZ
    J Formos Med Assoc; 1999 Mar; 98(3):201-4. PubMed ID: 10365540
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Gender- or age-related binding characteristics of valproic acid to serum proteins in adult patients with epilepsy.
    Kodama Y; Kodama H; Kuranari M; Tsutsumi K; Ono S; Yukawa E; Fujimura A
    Eur J Pharm Biopharm; 2001 Jul; 52(1):57-63. PubMed ID: 11438424
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Diurnal fluctuations in free and total plasma concentrations of valproic acid at steady state in epileptic patients.
    Riva R; Albani F; Cortelli P; Gobbi G; Perucca E; Baruzzi A
    Ther Drug Monit; 1983 Jun; 5(2):191-6. PubMed ID: 6410545
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.